Tinea Capitis: Fungal Scalp Infections in Children

Clinical Overview

Tinea capitis is a dermatophyte infection of the scalp and hair shafts, predominantly affecting children (peak incidence 3-14 years), though it can occur at any age. The condition presents with scaling, erythema, alopecia (hair loss), and occasionally pustulation on the scalp and may extend to eyebrows and eyelashes. Tinea capitis manifests in variable clinical types depending on host-organism interaction: non-inflammatory type with scaling and gradual hair loss (microsporum canis infection), inflammatory type with marked pustulation and suppuration (kerion formation), and seborrheic-like type with minimal inflammation but prominent scaling. The condition is contagious and represents a significant public health concern given prevalence in school-age children and rapid transmission in communal settings. Unlike tinea corporis treatable with topical agents, tinea capitis typically requires systemic antifungal therapy to achieve reliable cure, as topical agents penetrate scalp insufficiently. Early recognition and systemic therapy prevent permanent scarring alopecia (which can rarely develop with severe inflammatory disease) and reduce transmission to other children.

Epidemiology

Tinea capitis affects approximately 3-8% of children in developed nations (higher in some populations: up to 10-40% in children in some urban communities, particularly among African American children). Peak incidence occurs at 3-14 years of age, with incidence declining sharply after puberty (rare in adults). Female predominance is slight (approximately 1.1-1.3:1). Geographic and ethnic variation is substantial: higher prevalence in urban settings, African American and Hispanic populations (due to prevalence of specific organisms, particularly Trichophyton tonsurans in North America), and developing nations where incidence reaches 20-40%. Causative organisms vary geographically: Trichophyton tonsurans predominates in North America (responsible for >70% of cases), while Microsporum audouinii is common in Europe, and Microsporum canis is found worldwide. Risk factors include: young age, contact with infected individuals or animals (cats with microsporum canis), poor hygiene, immunocompromised status, and close contact in communal settings (schools, playgrounds, daycare). Family transmission is common; approximately 50-75% of children with tinea capitis have exposure to infected family members.

Pathophysiology

Tinea capitis develops through dermatophyte invasion of hair shaft and follicular epidermis. Two patterns of invasion occur: endothrix (organism invades hair interior) and ectothrix (organism invades hair surface), with clinical and epidemiologic implications. Endothrix pattern is characteristic of Trichophyton tonsurans (predominant North American organism) and causes non-inflammatory type disease; ectothrix pattern is characteristic of microsporum species and often causes more inflammatory responses. Dermatophytes produce keratinolytic enzymes allowing invasion of scalp epidermis and hair. The inflammatory response varies considerably: minimal response results in scaling without pustulation (non-inflammatory type), while pronounced host immune response results in marked inflammation, pustule formation, and suppurative drainage (kerion, representing host hypersensitivity response). Th1-mediated immune response is essential for controlling infection; children with impaired cell-mediated immunity show severe, persistent disease. Barrier disruption from inflammation allows secondary bacterial colonization (Staphylococcus aureus, Streptococcus pyogenes) in 5-10% of cases. Histologically, invasive hyphae are visible within hair and follicular epidermis; the pattern of invasion (endo- vs ectothrix) is diagnostically important.

Clinical Presentation

Tinea capitis presents with scaling, erythema, and alopecia on scalp, often with variable pruritus. Clinical presentation varies: non-inflammatory type shows minimal erythema with fine scaling and gradual, patchy alopecia; inflammatory type shows marked erythema, pustulation, exudation, and suppurative drainage. Kerion—severe suppurative type showing boggy pustular plaque with oozing—represents intense host immune response and warrants careful management to prevent scarring alopecia. Involved hair typically breaks off at scalp surface, creating short stubs ("black dots" appearance with endothrix organisms like T. tonsurans, or powdery scale appearance with ectothrix organisms). Scalp may demonstrate regional lymphadenopathy, particularly posterior cervical and occipital nodes. Pruritus is variable (present in 50-70% of cases). Extension to eyebrows and eyelashes may occur. Secondary bacterial infection manifests as increased pustulation, purulent drainage, systemic signs of infection, or regional lymphadenitis. The course without treatment is variable: some cases resolve spontaneously over months to years, while others persist indefinitely. Permanent scarring alopecia can rarely develop with severe inflammatory disease if inadequately treated.

Diagnosis

Diagnosis of tinea capitis requires clinical suspicion combined with confirmatory microbiologic testing. Key diagnostic features include: (1) scaling, erythema, and/or alopecia on scalp; (2) short hair stubs or characteristic appearance; (3) regional lymphadenopathy; (4) KOH preparation showing fungal elements; (5) fungal culture identifying organism. Potassium hydroxide preparation obtained by plucking (not cutting) affected hairs and scales shows fungal elements (hyphae, spores) under microscopy (sensitivity 40-60%). Fungal culture on Sabouraud dextrose agar or DTM is essential for confirming diagnosis and identifying organism (important for epidemiologic purposes and guiding therapy in treatment-resistant cases); sensitivity approaches 90% when appropriate specimens obtained. Dermoscopy may reveal characteristic features. Wood lamp examination shows blue-green fluorescence in occasional Microsporum infections but not in Trichophyton tonsurans (non-fluorescent); therefore, negative Wood lamp does not exclude diagnosis. Differential diagnosis includes: seborrheic dermatitis (usually less inflammation, no alopecia), psoriasis, bacterial folliculitis, and alopecia areata (distinguished by smooth alopecia without scale and autoimmune pathophysiology).

Treatment Algorithm

Tinea capitis treatment requires systemic antifungal therapy; topical agents alone are inadequate for reliable cure due to poor scalp penetration and inability to reach organisms within hair follicles.

Systemic antifungals are first-line therapy. Terbinafine is increasingly preferred for tinea capitis: dosing is weight-based (125 mg daily for 20-40 kg, 250 mg daily for >40 kg) for 4 weeks for trichophyton species (including predominant T. tonsurans) and 6 weeks for microsporum species. Griseofulvin is traditional therapy with microsize formulation 20-25 mg/kg/day or ultramicrosize 10-15 mg/kg/day for 6-8 weeks; superior efficacy for microsporum infections, though more modest for trichophyton. Itraconazole 5 mg/kg/day for 4 weeks is effective alternative. Newer triazoles including fluconazole show promise but are not yet first-line. Systemic antifungal therapy should continue for full recommended duration (4-8 weeks depending on agent and organism) to prevent relapse; shorter courses have relapse rates of 20-40%.

Adjunctive topical therapy may enhance efficacy: antifungal shampoos (selenium sulfide 2.5%, ketoconazole 2%) used twice weekly reduce spore load and potential transmission, though are not sufficient as monotherapy. Topical terbinafine 1% cream applied directly to scalp may provide modest additional benefit in some cases.

For severe inflammatory disease (kerion formation), short course of systemic corticosteroids may be considered to reduce inflammation and prevent scarring: prednis one 1 mg/kg/day for 5-7 days combined with systemic antifungal therapy (this is controversial; some experts recommend corticosteroids while others prefer avoiding them). Adjunctive antihistamines (cetirizine 5-10 mg daily for children) may reduce pruritus.

For secondary bacterial infection: culture-guided antibiotics are preferred; empiric oral cephalexin 25-50 mg/kg/day divided four times daily for 10-14 days is appropriate for non-severe infection.

School guidance: most experts recommend that children with tinea capitis can return to school while on systemic antifungal therapy (typically after 24-48 hours of therapy); the antifungal shampoos should be continued and child should avoid direct head-to-head contact. However, policies vary; parents should consult with school regarding specific requirements.

Prognosis

The prognosis of tinea capitis with appropriate systemic antifungal therapy is excellent: cure rates exceed 90% with recommended treatment duration. Factors influencing outcomes include: adherence to full treatment course (shorter courses have 20-40% relapse rates), organism type (trichophyton generally requires slightly shorter duration than microsporum), immunocompromised status (may require extended therapy), and severe inflammatory disease (kerion may require more intensive management). Permanent scarring alopecia is rare, occurring in <1% of treated cases and primarily in those with inadequately treated severe inflammatory disease. Relapse rates of 5-10% occur if therapy is discontinued prematurely or if sources of reinfection (infected individuals, fomites, animals) persist. In immunocompromised children (HIV with CD4 <200), immune reconstitution is essential for sustained remission.

When to See a Dermatologist

Initial evaluation by primary care provider is appropriate; dermatology referral is recommended for: (1) diagnosis confirmation if uncertain; (2) kerion formation; (3) treatment failure after 4-6 weeks of therapy; (4) severe inflammatory disease requiring specialist management; (5) immunocompromised children; (6) cases complicated by secondary bacterial infection.

Frequently Asked Questions

Q: Is tinea capitis contagious to other children? A: Yes, tinea capitis is contagious through direct contact or contaminated objects (combs, hats, pillows). Children on systemic antifungal therapy can typically return to school while continuing treatment and antifungal shampoos.

Q: Can my child get tinea capitis from a pet? A: Yes, microsporum canis infection (typically from cats) causes tinea capitis in children. If pet infection is suspected, veterinary evaluation and treatment may be necessary.

Q: How long does tinea capitis take to treat? A: Systemic antifungal therapy is typically required for 4-8 weeks depending on agent and organism. Clinical improvement is evident within 4-6 weeks, though complete resolution may require full treatment course.

Q: Can tinea capitis cause permanent hair loss? A: Permanent scarring alopecia is rare (<1% of treated cases). Temporary alopecia during infection resolves with effective treatment and hair regrowth occurs.

References